LIDDS AB (publ) (LIDDS.ST)
SEK 0.03
(-15.5%)
SEK 0.03
(-15.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.75 Million SEK | -64.47% |
| 2022 | 10.57 Million SEK | 49.58% |
| 2021 | 7.06 Million SEK | -37.99% |
| 2020 | 11.39 Million SEK | 91.05% |
| 2019 | 5.96 Million SEK | 22.76% |
| 2018 | 4.85 Million SEK | 36.48% |
| 2017 | 3.56 Million SEK | -58.06% |
| 2016 | 8.49 Million SEK | 229.98% |
| 2015 | 2.57 Million SEK | 10.96% |
| 2014 | 2.31 Million SEK | 47.07% |
| 2013 | 1.57 Million SEK | -55.24% |
| 2012 | 3.52 Million SEK | 107.08% |
| 2011 | 1.7 Million SEK | 42.38% |
| 2010 | 1.19 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.8 Million SEK | -19.34% |
| 2024 Q1 | 3.48 Million SEK | -7.35% |
| 2023 Q2 | 5.11 Million SEK | -14.23% |
| 2023 Q3 | 3.85 Million SEK | -24.64% |
| 2023 Q4 | 3.75 Million SEK | -2.62% |
| 2023 FY | 3.75 Million SEK | -64.47% |
| 2023 Q1 | 5.96 Million SEK | -43.55% |
| 2022 Q1 | 9.26 Million SEK | 31.14% |
| 2022 Q4 | 10.57 Million SEK | -3.51% |
| 2022 FY | 10.57 Million SEK | 49.58% |
| 2022 Q2 | 7.66 Million SEK | -17.32% |
| 2022 Q3 | 10.95 Million SEK | 42.96% |
| 2021 Q3 | 6.43 Million SEK | -21.32% |
| 2021 Q2 | 8.17 Million SEK | -20.49% |
| 2021 FY | 7.06 Million SEK | -37.99% |
| 2021 Q1 | 10.28 Million SEK | -9.78% |
| 2021 Q4 | 7.06 Million SEK | 9.87% |
| 2020 FY | 11.39 Million SEK | 91.05% |
| 2020 Q1 | 8.34 Million SEK | 39.94% |
| 2020 Q2 | 7.1 Million SEK | -14.88% |
| 2020 Q3 | 8.33 Million SEK | 17.37% |
| 2020 Q4 | 11.39 Million SEK | 36.66% |
| 2019 Q2 | 4.9 Million SEK | -7.59% |
| 2019 Q3 | 7 Million SEK | 42.66% |
| 2019 Q1 | 5.31 Million SEK | 9.32% |
| 2019 Q4 | 5.96 Million SEK | -14.82% |
| 2019 FY | 5.96 Million SEK | 22.76% |
| 2018 Q1 | 3.63 Million SEK | 2.01% |
| 2018 FY | 4.85 Million SEK | 36.48% |
| 2018 Q4 | 4.85 Million SEK | -18.43% |
| 2018 Q3 | 5.95 Million SEK | 30.24% |
| 2018 Q2 | 4.57 Million SEK | 25.94% |
| 2017 Q1 | 3.32 Million SEK | -60.87% |
| 2017 Q2 | 4.27 Million SEK | 28.66% |
| 2017 Q4 | 3.56 Million SEK | 35.53% |
| 2017 Q3 | 2.62 Million SEK | -38.54% |
| 2017 FY | 3.56 Million SEK | -58.06% |
| 2016 Q3 | 2.69 Million SEK | 131.9% |
| 2016 Q2 | 1.16 Million SEK | -40.45% |
| 2016 Q1 | 1.94 Million SEK | -24.29% |
| 2016 FY | 8.49 Million SEK | 229.98% |
| 2016 Q4 | 8.49 Million SEK | 215.62% |
| 2015 Q2 | 969 Thousand SEK | -45.22% |
| 2015 Q4 | 2.57 Million SEK | 70.28% |
| 2015 FY | 2.57 Million SEK | 10.96% |
| 2015 Q1 | 1.76 Million SEK | -23.71% |
| 2015 Q3 | 1.51 Million SEK | 55.93% |
| 2014 Q1 | 2 Million SEK | 27.35% |
| 2014 Q2 | 11.61 Million SEK | 478.64% |
| 2014 Q3 | 3.02 Million SEK | -73.98% |
| 2014 Q4 | 2.31 Million SEK | -23.29% |
| 2014 FY | 2.31 Million SEK | 47.07% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q4 | 1.57 Million SEK | 0.0% |
| 2013 FY | 1.57 Million SEK | -55.24% |
| 2012 FY | 3.52 Million SEK | 107.08% |
| 2011 FY | 1.7 Million SEK | 42.38% |
| 2010 FY | 1.19 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.76% |
| AcouSort AB (publ) | 10.37 Million SEK | 63.808% |
| Active Biotech AB (publ) | 13.4 Million SEK | 71.97% |
| Alzinova AB (publ) | 9.33 Million SEK | 59.747% |
| Amniotics AB (publ) | 10.54 Million SEK | 64.388% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 15.138% |
| BioArctic AB (publ) | 139.5 Million SEK | 97.308% |
| Camurus AB (publ) | 414.81 Million SEK | 99.095% |
| Cantargia AB (publ) | 54.97 Million SEK | 93.167% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 2.137% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 72.726% |
| Genovis AB (publ.) | 98.04 Million SEK | 96.169% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 79.691% |
| Mendus AB (publ) | 51.22 Million SEK | 92.668% |
| Kancera AB (publ) | 17.97 Million SEK | 79.108% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 67.534% |
| Lipum AB (publ) | 7.53 Million SEK | 50.172% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 27.181% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 96.97% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -59.22% |
| NextCell Pharma AB | 13.68 Million SEK | 72.562% |
| OncoZenge AB (publ) | 1.69 Million SEK | -121.071% |
| Saniona AB (publ) | 86.08 Million SEK | 95.637% |
| Simris Alg AB (publ) | 148.93 Million SEK | 97.478% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 90.807% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.221% |
| Xintela AB (publ) | 14.01 Million SEK | 73.2% |
| Ziccum AB (publ) | 6.38 Million SEK | 41.202% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 80.401% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 94.772% |
| CombiGene AB (publ) | 4.15 Million SEK | 9.625% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 94.719% |
| Intervacc AB (publ) | 21.68 Million SEK | 82.675% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 96.476% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 89.145% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 85.937% |
| Corline Biomedical AB | 6.78 Million SEK | 44.675% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 93.878% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 76.695% |
| Aptahem AB (publ) | 8.99 Million SEK | 58.257% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 91.867% |
| Fluicell AB (publ) | 8.91 Million SEK | 57.869% |
| Biovica International AB (publ) | 34.76 Million SEK | 89.197% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 67.809% |
| Abliva AB (publ) | 16.78 Million SEK | 77.618% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.25% |
| 2cureX AB (publ) | 2.93 Million SEK | -27.973% |
| I-Tech AB | 16.2 Million SEK | 76.822% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.683% |
| Cyxone AB (publ) | 4.69 Million SEK | 19.983% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 71.819% |
| Biosergen AB | 5.08 Million SEK | 26.136% |
| Nanologica AB (publ) | 79.32 Million SEK | 95.265% |
| SynAct Pharma AB | 51.83 Million SEK | 92.754% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 52.749% |
| BioInvent International AB (publ) | 90.45 Million SEK | 95.848% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 27.699% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.932% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -109.365% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 70.527% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 48.264% |